Introduction
Women account for one half of new HIV-1 infections worldwide (Joint United Nations Programme on HIV/AIDS 2013). The use of contraceptive pills by HIV-1-seropositive women is considered to be important for preventing unintended pregnancies and reducing mother-to-child transmissions. Although these hormones help to prevent unintended pregnancies, they also enhance HIV-1 acquisition (Ramjee & Wand 2012 , Morrison et al. 2015 . Several epidemiological reports are inconsistent for progesterone-containing contraceptive use and risk of HIV-1 acquisition. A prospective study from seven African countries followed 2269 chronically HIV-1-infected women and showed no increased risk of HIV-1 disease progression for women on contraceptives compared with women who did not receive any contraceptive. In addition, this study observed no statistical difference in oral or injectable contraceptive use (Heffron et al. 2012 (Heffron et al. , 2013 . However, another study reported that injectable depot medroxyprogesterone acetate (DMPA) use had a moderate risk of HIV-1 acquisition, but not the oral hormonal contraception (Morrison et al. 2012) . Based on these available data, in 2012, the World Health Organization released a technical statement noting that the data on hormonal contraceptives were inconclusive and recommending those women who are either at high risk or living with HIV-1 to continue the use of hormonal contraceptives. After the WHO report, several research studies indicated the risk associated with hormonal contraceptives. The study from South African population-based data on the use of hormonal contraceptive indicated a 12% increase in HIV-1 seroconversions after correcting for other HIV-1 risk variables (Ramjee & Wand 2012) . A pigtail model indicates higher susceptibility of HIV or SHIV during luteal phase (high progesterone levels) when macaques are intravaginally challenged with SHIV (Vishwanathan et al. 2011) . Recently, a study on hormonal contraception and HIV acquisition reports individual patient data of several studies. Meta-analysis indicates that DMPA may increase HIV acquisition (controlling confounders and adjusted odds ratio of 1.5) compared with other methods of contraception (Morrison et al. 2015) . In vitro studies on hormone effects support the clinical studies discussed earlier. A study showed progesterone decreased CCR5 expression and increased CXCR4 expression in PBMCs of HIV-uninfected and -infected patient samples cultured with progesterone suggesting progesterone may modulate HIV infection at receptor level (Cabrera-Munoz et al. 2012) . We also observed in our previous in vitro study that progesterone augments replication and transmission of major HIV-1 subtypes (Ragupathy et al. 2013) .
It has been shown that among HIV-1-infected women, HSV-2 co-infection is the most common sexually transmitted infection (STI). HSV-2 is the causative agent for genital herpes in humans and a major co-factor for HIV-1 acquisition (Wald & Link 2002) . HIV-1 and HSV-2 are considered to be synergistic pathogens, and genital herpes increases susceptibility to HIV-1. HIV-1 co-infection is known to affect HSV-2 shedding, reactivation rates and HSV-2 infectivity (Foss et al. 2011) . In women, HSV-2 co-infection increases the risk of HIV-1 infection (Benjamin et al. 2008 , Thurman & Doncel 2012 . The role of progesterone and HSV-2 co-infection was reported from a study from Kenya where both HSV-2 and oral contraceptives increase HIV-1 acquisition. In addition, contraceptive use and risk of HIV-1 acquisition are not associated with HSV-2 seropositivity (Baeten et al. 2007) .
It is well known that susceptible cells infected with HIV-1 undergo apoptosis-mediated cell death. We had previously shown that an anti-apoptotic Bcl-2 family protein, Bcl-XL, and other proteins are able to decrease HIV-1 replication significantly suggesting that change in expression of this protein may affect HIV-1 replication in susceptible cells (Wang et al. 2010) . Several other studies indicated that the Bcl-2 molecule inhibits the normal apoptotic pathway to cell death and extends the life span of certain cells (Tsujimoto 1998 , Czabotar et al. 2013 . Similarly, HSV-2 can infect a variety of cell types, and productive infection is characterized by apoptosis and downregulation of Bcl-2 (Sciortino et al. 2006) . Previous studies focusing the effects of progesterone on the female reproductive tract indicated that it regulates the activities of endometrial epithelial, stromal cells and spiral arteries to modulate blood flow during pregnancy (Perrot-Applanat et al. 1994) . It has also been shown to exert immunomodulatory effects on T-and B-cells (Kyurkchiev et al. 2014) . Studies on uterine leiomyoma tissues reported that Bcl-2 mRNA and protein levels might be regulated by progesterone (Yin et al. 2007 ). These studies indicate that progesterone levels affect the metabolism of cells. However, limited knowledge is available regarding the effects of progesterone on replication of pathogens.
In this study, we demonstrate that progesterone increases the replication of HIV-1 or HSV-2 by changing cellular proteins. Understanding the mechanisms behind progesterone use, HSV-2 co-infection and HIV-1 susceptibility and identifying new biomarkers that may be useful for assessing the risk of increased HIV-1 acquisition are important public health issues that may be critical for the development of successful HIV-1 prevention efforts.
Material and methods

Cells and viruses
The T-cell line (lymphoblastoid leukemia cell) CEMss was obtained from NIH AIDS Reagent Program (Cat No: 776) and cultured in RPMI-1640 medium supplemented with 10% FBS (charcoal stripped), 2 mM glutamine, 100 U/mL of penicillin and 100 U/mL streptomycin. Peripheral blood mononuclear cells (PBMC) from three HIV-1 seronegative female blood donors were isolated from buffy coat received from NIH Blood Bank. Before blood draw, informed consent was obtained from all of the healthy, normal blood donors according to the ethical principles of international ethical guidelines for biomedical research involving human subjects. We used our standard laboratory protocol for PBMC isolation from buffy coat (Zhang et al. 2008) . Briefly, PBMCs were isolated by Ficoll/ Hypaque density-gradient centrifugation. Monocytes (>95%) were removed by adherence to the culture flasks, and the remaining peripheral blood lymphocytes (PBL) were stimulated with 2 μg/mL PHA for 3 days to activate T-cells before infection. The PBL or PBMC was cultured in RPMI-1640 supplemented with 15% FBS, 2 mM glutamine, 100 U/mL of penicillin, 100 U/mL of streptomycin and 5 U/mL of human interleukin-2 (Roche). Cell numbers were determined using Invitrogen Countess Automated Cell Counter, and cells stained with trypan blue were considered as dead cells.
The HIV-1IIIB strain was obtained from NIH AIDS Reagent Program and propagated in CEMss cells. HSV-2 strain MS was kindly contributed by Dr Jerry Weir, (FDA/CBER, Silver Spring, MD, USA) and propagated in the mammalian Vero cell line (derived from the kidney of a normal African green monkey) obtained from the American Type Culture Collection (ATCC). HSV-2 standard (Cat No: VR540D) for the TaqMan assay was purchased from ATCC. Serial dilutions were prepared in the ranges of 10-10 5 pg/mL of dsDNA.
Sex steroid hormones
Two hours before infection, physiological levels of sex steroid hormones were added to cells. Steroid hormones were prepared as per manufacturer instructions, and the solvents were dried and diluted in the culture medium. For all hormone experiments, final concentrations are used as follows: progesterone (Sigma, P7556) 500 pM, β-estradiol (Sigma, E2257) 20 nM and testosterone (Sigma, T5411) 4 nM. No hormone controls has equal amount of either air-dried 100% ethanol (without E 2 ) dissolved in culture medium or a culture medium (without P 4 ). Further, hormone concentrations were maintained throughout the culture by supplementing hormonetreated media at each experimental time point after initial infection. However, hormones fluctuate in vivo or between the individuals which cannot be depicted in ex vivo studies. The focus here is to demonstrate the effects of selected physiological levels hormones on virus infection kinetics.
Antivirals
AZT (3′-azido-2′,3′-dideoxythymidine) (Cat; A7803) and Valacyclovir hydrochloride hydrate (Cat: V9889) were purchased from Sigma. For inhibition studies, we used AZT IC 50 5 µg/mL and valacyclovir EC 50 0.9 µg/mL of culture media.
Antibodies and Western blot analysis
Rabbit monoclonal antibodies against BCL2L1 (Clone E18) and CASP3 (Clone E87) were purchased from OriGene Technologies, Inc, Rockville, MD, USA. Western Blot analysis was carried out as described previously (Wang et al. 2012) . After blocking, the blot was incubated for 2 h with mAb to rabbit BCL2L1 or CASP3 and horseradish peroxidase conjugated. Antibody binding was detected by chemiluminescence staining using the ECL detection kit (Amersham Biosciences).
Experimental design
CEMss cells are susceptible to infection with HIV-1 and HSV-2 as described previously (Legoff et al. 2007 ). These cells were seeded at 1 × 10 5 /mL of culture medium in five 75 mL flasks. One flask served as the uninfected control, and the remaining four were infected with HIV-1 (5 or 10 ng/mL of HIV-1 p24) or HSV-2 (1 or 2 pfu/cell) or HIV-1 followed by HSV-2 or HSV-2 followed by HIV-1. Cells were infected for 4 h total at 37°C and 5% CO 2 , washed and cultured. A total of 200 µL culture supernatant were collected from each flask and marked as day 0. Similar set of experiments were performed for progesterone (hereafter called as P 4 ), estradiol (hereafter called as E 2 ), progesterone-estradiol mix (hereafter called as E 2 /P 4 ) and testosterone hormone treatment. To monitor infectivity, 1mL culture supernatant was collected at 4, 7, 14 or 21 days after infection to measure HIV-1 p24 antigen levels or tested by a multiplex in-house HIV-1-1/HSV-2 TaqMan assay.
HIV-1 p24 determinations
We used the Perkin-Elmer HIV-1 p24 Elisa Kit, Cat No: NEK050B001 for p24 measurements. All procedures were followed as per the manufacturer's instructions. Because p24 test kits were optimized for quantification in a narrow range of 200-12.5 pg/mL, most of the culture supernatants were diluted in culture media to 1:10, 1:100 and 1:1000 before quantification.
Real-time TaqMan
Real-time quantitative PCR was performed on a 7500 Applied Biosystems Thermal Cycler in a 25 µL reaction mix containing 1 µL cDNA, 1× TaqMan QuantiTect Probe PCR Master Mix and 1X K15 or BAX or GAPDH assay. Thermal cycling was carried out at 50°C for 2 min, 95°C for 10 min, followed by 40 cycles at 95°C for 15 s, and 60°C for 1 min. All samples were run in duplicate. To determine the viral load of the two viruses in a single assay, we developed a multiplex quantitative TaqMan assay. For standard curve, HIV-1 (Cat No: 3443) was obtained from NIH AIDS Reagent and HSV-2 (Cat. No: VR-540D) from ATCC. Our multiplex TaqMan PCR was designed using the following primers and probes HSV-2 and HIV-1. Primers for HIV-1 included: (114 bp) gag gene F-ACCCATGTTTACAGCATTATCAGAAG, R-GCTTGATGTCCCCCTACTGTATTT; probe FAM, AGCC-ACCCCACAAGATCTAAACACCATGT-MGB; for HSV-2 (118 bp), HSV-2 (333) glycoprotein B gene Acc. No: M15118, F-TGCAGTTTACGTATAACCACATACAGCR-AGCTTGCGGGCCTCGTT; VIC-CGCCCCAGCATGTCG TTCACGT-MGB. The formula for measuring the concentration of HSV-2 DNA is 6.02 × 10 23 (copies/mol) × A260 (ng/mL)/(DNA length × 650) = copies/mL. With several repeated experiments, we optimized the assay conditions to quantify both these viruses through derivation of a standard graph.
PCR arrays
RNA was prepared from cell pellets using the RNeasy Mini Kit (Cat: 74104) from Qiagen after homogenization. The RNA samples were DNase I (Roche Laboratories) treated and further purified on a column from an RNeasy kit (Qiagen). Reverse transcription was carried out using a QIAGEN RT2 first-strand kit (Cat No: 330401) using 1 μg RNA. The inflammatory cytokine-chemokine 'RT2 profiler array' from SA Biosciences was used to measure the transcript levels of various cytokines. The array contains primer sets for 84 cytokines/chemokines (PAHS-011A-24) and appropriate housekeeping controls. We also performed similar analysis for HIV-1 infection and host responses (PAHS-012A). Real-time PCR was carried out as described by the manufacturer, using an Applied Biosystems T7500 Thermal Cycler.
The mRNA expression level for each gene was normalized using the expression of HPRT as a control housekeeping gene and compared with the data obtained with the negative control (RNA from uninfected cells) according to the 2 −ΔΔct method (Livak & Schmittgen 2001) . Results were considered significant when relative mRNA expression was twofold higher or lower than that of the uninfected cells. The results were confirmed by quantitative real-time PCR on individual RNA samples using the QuantiTect SYBR Green PCR Kit (Qiagen) and the same sets of primers as used in the PCR cytokine array (S A Bioscience Corporation, Frederick, MD, USA).
Electrophoretic mobility shift assay
CEMss cells were treated for 2 h with P 4 as indicated earlier. Nuclear protein was extracted from whole cells using NE-PER nuclear and cytoplasmic extraction reagents (Pierce). EMSA was performed using a LightShift Chemiluminescent EMSA kit (Pierce). In EMSA, we used previously published (Yin et al. 2007) sequence of the double-stranded oligonucleotide 5-GACAGAGGATCATGCTGTACTTAAA-3, which is identical to the 25-bp-long sequence (−559/−535 bp) within the promoter region of the Bcl-2 gene. This sequence contains an imperfect 15-bp palindromic PRE (553/539). The mutant probe is an unlabeled 25-bp oligonucleotide, in which 3 bp of the 15-bp PRE at −549, −543 and −540 positions were replaced by As (GACAAAGGATAATACTGTACTTAAA).
Biotin endlabeled oligonucleotide probes were synthesized from the CBER core facility and annealed to the complementary oligonucleotides. Hundred pico moles labeled probe and 5 µg nuclear extract were incubated for 20 min at room temperature in a reaction mix containing 5% (vol/vol) glycerol, 10 mM Tris-HCl, 50 mM NaCl, 1 mm MgCl 2 , 0.5 mm dithiothreitol and 2 g poly (dI-dC). For the EMSA, unlabeled wild-type or mutant probe (4 pmol) was added simultaneously with the labeled probe. Nondenaturing polyacrylamide gels (5%) were used to resolve protein-DNA complexes. Protein-DNA samples were transferred to the Biodyne B precut modified nylon membrane (Pierce). Protein-DNA complexes were detected using a LightShift Chemiluminescent EMSA Kit (Pierce) and exposed to the CL-XPosure film (Pierce).
Statistical analysis
The statistical module Prism, version 5.0 (GraphPad Software) was used to perform unpaired two-tailed Student's t-test with group sizes of two or analysis of variance (ANOVA) with Bonferroni post hoc t-test for greater than two group sizes.
Results
Infectivity of HIV-1 and HSV-2 and multiplex TaqMan
To determine the HIV-1 viral load from CEMss cells in the presence of hormone or HSV-2, cells were exposed to HIV-1 (10 ng p24/mL) and HSV (2 pfu) either alone or together. Two hours before infection, an aliquot of cells were exposed to physiological levels of hormone also. HIV-1 viral load quantification was carried out using two different assays, the HIV-1 p24 Ag ELISA and Real-time TaqMan Assay. At 7 d.p.i (days post infection) the means of HIV-1 p24 levels were higher ( Fig. 1A ) for cells treated with E 2 (1229.1 pg/mL) and significantly (P < 0.05) higher P 4 (1411.2 pg/mL) relative to NH (993.1 pg/mL). However, no significant differences were noted for cultures treated with E 2 /P 4 mix (1076.7 pg/mL) and testosterone (876.5 pg/mL). HSV-2 co-infection commonly occurs with HIV-1 and shares the same sexual route of transmission. We investigated when the HSV-2-infected cells were superinfected with HIV-1 and measured the HIV-1 viral load at 7 d.p.i. HIV-1 p24 level means were significantly (P < 0.05) lower (Fig. 1A ) for cells treated with E 2 (508 pg/mL), E 2 /P 4 mix (346.8 pg/mL), testosterone (350.5 pg/mL) and very significantly lower (P < 0.01) for P 4 (190.9 pg/mL), relative to NH (770.4 pg/mL).
In this study, we used two virus types; to quantify both these viruses simultaneously, we used multiplex TaqMan Assay. Nucleic acids were extracted from culture supernatants to quantify both HIV-1 and HSV-2. Like HIV-1 p24 assay, similar trend was observed with TaqMan Assay although TaqMan is not true measure of infectivity. At 7 d.p.i increased levels of HIV-1 RNA (Fig. 1B ) for cells treated with E 2 (2.81 log 10 cps/mL), P 4 (3.22 log 10 cps/mL), E 2 /P 4 mix (3.06 log 10 cps/mL) and testosterone (2.78 log 10 cps/mL) relative to NH (2.72 log 10 cps/mL). Although no significant differences were noted for E 2 and testosterone, P 4 viral load was significantly higher (P < 0.05). In HSV-2 co-infection, HIV-1 viral load was lower (Fig. 1B ) for cells treated with P 4 (1.86 log 10 cps/mL), E 2 /P 4 mix (2.39 log 10 cps/mL) and testosterone (2.38 log 10 cps/mL) relative to NH (2.66 log 10 cps/mL). However, for E 2 (2.50 log 10 cps/mL), no difference in viral load was noted in comparison with NH.
Once we determined that viral load was quantifiable with or without hormone treatment using multiplex TaqMan, we focused on specifically quantifying each of these viruses in the presence and absence of hormones. In addition, due to assay limitations and high viral load at day 7, in rest of the long-term experiments, virus infectivity dose was reduced to half for optimal quantifications. Infected cells were either not hormone treatment (NH) or treated with hormones estradiol (E 2 ), progesterone (P 4 ), a mix of estradiol with progesterone (E 2 /P 4 Mix) and testosterone. Statistical significance was derived by comparing NH with hormone-treated groups. (A) Measurement of HIV-1 by quantitative enzyme immuno p24 assay. HIV-1 viral loads of cells treated with different hormone types were compared with cells treated with no hormone. Although differences in HIV viral load noted comparing NH with hormone treatment only P 4 treatment had significantly (*P < 0.05) higher viral load. Similar experiments were repeated for HSV-2/HIV-1 co-infected cells. Significant (*P < 0.05) low viral load was noted for hormone-treated groups and very significant (**P < 0.01) reduction in viral load was noted for P 4 -treated group. But for E 2 -treated cells, there were no significant differences in viral load when compared with NH. (B) Measurement of HIV-1 by quantitative TaqMan assay indicating similar trends of viral load differences for P 4 -and E 2 /P 4 mix-treated cells with HIV or HSV-2/HIV-1 co-infection. However, no statistical significance noted for HIV-infected cells treated with E 2 or testosterone. In co-infected cells, P 4 (**P < 0.01), mix and testosterone treatment showed significant (*P < 0.05) viral load differences. No significant differences were noted for E 2 compared with NH. The error bars represent standard errors of the means (s.e.m.) for triplicate measurements of at least three experiments. 
Effects of hormone-treated cells and virus replication
Cells exposed to HIV-1 and HSV-2 was cultured up to 14 days, and viral load was quantified at two intervals to study the hormone effects on replication kinetics. HIV-1 viral load in terms of RNA cps/mL were represented in log 10 values. Although two time points were measured, infectivity was delayed for certain culture conditions; hence, data were shown only for measurements at day 14. As noted earlier, HIV-1 RNA cps/mL means were significantly higher ( Fig. 2A ) at 14 d.p.i (P < 0.01) for cells treated with E 2 (3.9 log 10 cps/mL), P 4 (3.61 log 10 cps/mL), E 2 /P 4 mix (3.52 log 10 cps/mL) and testosterone (3.51 log 10 cps/mL) relative to NH (2.39 log 10 cps/mL). Similarly, HSV-2 DNA level means were significantly higher (P < 0.05) (Fig. 2B ) for cells treated with E 2 (12.24 log 10 cps/mL), E 2 /P 4 mix (12.41 log 10 cps/mL) and nonsignificant levels for P 4 (11.1 log10 cps/mL) and testosterone (10.76 log 10 cps/mL) relative to NH (10.74 log 10 cps/mL).
Next, we performed co-infection studies with HIV-1 infection followed by HSV-2 or vice versa to determine which co-infection augments the pathogenesis of HIV-1. The experiments were performed with and without hormone treatment to study viral replication kinetics.
As described earlier, the mean HIV-1 RNA was significantly higher (Fig. 2C ) at 14 d.p.i (P < 0.05) with P 4 (3.42 log 10 cps/mL), E 2 /P 4 mix (3.57 log 10 cps/mL) and testosterone (3.47 log 10 cps/mL) relative to NH (2.47 log 10 cps/mL) but nonsignificant with E 2 (2.85 log 10 pg/mL). When HIV-1 infected cells were superinfected with HSV-2, HIV-1 viral load was significantly higher (Fig. 2D ) for E 2 (3.66 log 10 cps/mL), P 4 (3.68 log 10 cps/mL), E 2 /P 4 mix (3.45 log 10 cps/mL) and testosterone (3.45 log 10 cps/mL) relative to NH (2.23 log 10 cps/mL). It was observed that there were no significant differences (P > 0.05; 0.93) in HIV-1 viral load in cells infected with HSV-2 first and later infected with HIV-1 or vice versa. HIV-1 RNA was little higher (2.74 log 10 cps/mL) in HIV-1 superinfection of HSV-2-infected cells relative to NH (2.39 log 10 cps/mL). In all subsequent co-infection experiments, cells were first infected with HSV-2 followed by HIV-1. In co-infected cells treated with P 4 , mean HIV-1 viral load (3.68 log 10 pg/mL) Similarly, cells were infected with HSV-2 virus, and its replication was measured and compared for hormone-treated and -untreated cells. HSV-2 replication was significantly (P < 0.05) higher at 14 d.p.i in cells treated with E 2 or E 2 /P 4 mix but nonsignificant with P 4 or testosterone. (C) Cells were first infected with HSV-2 (2 h) and co-infected with HIV-1 (2 h) or vice versa (D). In (C) compared with cells treated with no hormone, significant (P < 0.05) increase in HIV-1 titer was seen with cells treated with P 4 , testosterone and E 2 /P 4 mix but nonsignificant (ns) for E 2 -treated cells. (D) All hormone-treated cells had significant increase (P < 0.01) of HIV-1 viral load compared with NH.
at day 14 was relatively higher compared with NH (2.74 log 10 pg/mL). In addition, co-infection experiments with P 4 -treated cultures showed extensive cell death.
We further analyzed the effects of P 4 either alone or in combination with estradiol and simultaneously measured the cell viability. Analysis was performed for two time points, day 7 and 14. At day 7, the mean HIV-1 p24 of NH was 563.2 pg/mL, P 4 , 776 pg/mL; E 2 /P 4 mix, 427 pg/mL and cell viability for each experimental condition was 81-84% (Fig. 3) . At day 14, mean HIV-1 p24 of NH was 1119.5 pg/mL, P 4 , 721 pg/mL; E 2 /P 4 mix, 593 pg/mL and cell viability was significantly (P < 0.05) lower for P 4 (42%) and E 2 /P 4 mix (35%) than for NH (66%).
Next, we determined the cell viability using an automated cell counter at three different time points of multiple experimental conditions (Fig. 4) . Equal numbers of cells were either infected with HIV-1 or HSV-2 or uninfected and treated with P 4 alone or together with estradiol. At days 7 and 9, cell viability was 80-92% in all experimental conditions. However, at day 14, the viability dropped to 35-88% and more specifically HSV-2/HIV-1 cultures treated with P 4 had significantly (P < 0.05) lower percent of viable cells compared with uninfected P 4 -treated cells. The extensive cell death of cultures with co-infection and P 4 treatment may likely be due to the involvement of cellular factors.
Reduced efficacy of antivirals for virus-infected cells treated with P 4
We further determined the effect of treatment with antivirals on P 4 -exposed cells infected with HIV-1 or HSV-2/HIV-1. Infected cells were cultured with and without P 4 treatment for 7 days, and a subset of cells were treated with AZT for HIV-1 and AZT/Valacyclovir for co-infections of HSV-2/HIV-1. The baseline HIV-1 viral load (without ARVs) at day 7 was 0.21 ng/mL for P 4 -untreated cells and 0.27 ng/mL of p24 for P 4 -treated cells and in co-infection, 0.55 ng/mL for cells not treated with P 4 and 0.645 ng/mL of p24 for P 4 -treated cells confirming that there was productive HIV-1 infection.
The cultures were split into two for antiviral treatment and no treatment. The HIV-1 p24 levels for AZT-treated cultures had significantly lower HIV-1 p24 levels (means of: day 10 = 0.29; day 14 = 0.29; day 21 = 0.48 ng/mL) than cultures without AZT (means of HIV-1 p24: day 10 = 0.29; day 14 = 2.48; day 21 = 5.92 ng/ mL) (Fig. 5A) . When similar experiments were repeated for P 4 -treated cells (Fig. 5A) , HIV-1 viral load was 5-fold higher (P < 0.01) at day 21 (29.3 ng/mL of p24) compared Cell viability (Day 14)
Figure 3 HIV-1 p24 levels were measured in cells untreated (NH) or treated with P 4 or E 2 /P 4 mix and compared with cell viability. These cells were co-infected with HSV-2, and experiments were performed at similar conditions. HIV-1 virus titer was measured at two time points, days 7 and 14, and data are shown as bar graph (primary axis). Cell viability (trypan dye exclusion) was measured using automated cell counter and plotted as percentages (in right y-axis). At day 7, >80% of cells were viable in untreated or hormone-treated cells, whereas HIV-1 viral load was little higher in P 4 -treated cells (802 pg/mL) compared with NH (525 pg/mL) or E 2 /P 4 (410 pg/mL) mix. At day 14, spontaneous loss of viable cells was observed (P < 0.05) with P 4 -and E 2 /P 4 mix-treated cells (line graph) and no significant rise in HIV-1 p24 levels (bar graph). Results shown are the mean (s.e.m.) from three different replicates of at least three experiments. 
Figure 4
Cell viability under different experimental conditions. Cells were either uninfected (negative control) or infected and hormones treated as indicated. Cells viability (trypan dye exclusion) was measured at three time points, day 7, 9 and 14 using automated cell counter. Significant cell death (P < 0.05) was noted with P 4 -treated cells and co-infected with HSV/HIV. Error bars represent the standard errors of the means, and asterisks indicate cells that are significantly low viable cells as determined by ANOVA.
with that of cultures without P 4 (5.92 ng/mL of p24). In addition, HIV-1 p24 levels did not decrease completely with AZT treatment (day 10 = 0.44; day 14 = 1.67; day 21 = 2.26 ng/mL) compared with those in cultures without AZT (means of HIV-1 p24: day 10 = 3.70; day 14 = 12.23; day 21 = 29.30 ng/mL). Moreover, in P 4 -treated cells, AZT efficacy was lower (means of HIV-1 p24: day 14 = 1.67; day 21 = 2.26 ng/mL) than in cultures without P 4 (P < 0.001) (means of HIV-1 p24: day 14 = 0.29; day 21 = 0.48 ng/mL).
Similarly, in co-infections, the HIV-1 p24 levels for AZT/valacyclovir-treated cultures were significantly lower (means of HIV-1 p24: day 10 = 0.22; day 14 = 0.38; day 21 = 0.65 ng/mL) than those for cultures without AZT/valacyclovir (means of HIV-1 p24: day 10 = 0.55 ng/mL; day 14 = 0.57; day 21 = 13.1 ng/mL) (Fig. 5B) . When similar experiments were repeated for P 4 -treated cells (Fig. 5B) , HIV-1 viral load was 9-fold higher (P < 0.001) at day 21 (137.1 ng/mL of p24) compared with that in cultures without P 4 (15.11 ng/mL of p24). In addition, HIV-1 p24 levels did not decrease completely with AZT/valacyclovir treatment (day 10 = 0.55; day 14 = 0.57; day 21 = 13.12 ng/mL) compared with cultures without AZT/valacyclovir (means of HIV-1 p24: day 10 = 3.60; day 14 = 12.48; day 21 = 137.12 ng/mL). Moreover, in P 4 -treated cells, AZT/valacyclovir efficacy was lower (means of HIV-1 p24: day 14 = 0.57; day 21 = 13.12 ng/mL) than that in cultures without P 4 (P < 0.001) (means of HIV-1 p24: day 14 = 0.38; day 21 = 0.65 ng/mL).
P 4 supports HIV-1 replication and cell death
Next, we wanted to study the effects of P 4 treatment on primary cells and determine whether P 4 treatment or HSV-2 co-infection increased HIV-1 replication and augmented cell death. We cultured PBMC cells collected from three different donors and treated them with P 4 at similar concentrations of hormones used in the experiments with cell lines. The PBMC cells not treated with hormones served as a control. At 14 d.p.i P 4 -treated mean of HIV-1 p24 levels of donor 2 (81.6 ng/mL) and donor 3 (126.9 ng/mL) was significantly (P < 0.05) higher than with NH donor 2 (62 ng/mL) and donor 3 (61.5 ng/mL). However, no significant differences were observed between P 4 -treated donor 1 (90 ng/mL) and NH donor 1 (80.6 ng/mL) (Fig. 6A) , suggesting donor-to-donor variations in infectivity. When similar experiments were repeated for HSV-2 co-infection, at 14 d.p.i. significant (P < 0.05) cell death and low HIV-1 p24 levels were noted for P 4 -treated donor 1 (990 pg/mL), donor 2 (1160 pg/mL) and donor 3 (1880 pg/mL) compared with NH donor 1 (5000 pg/mL), donor 2 (6500 pg/mL) and donor 3 (7240 pg/mL) (Fig. 6B) . These results suggest that P 4 enhances HIV-1/HSV-2 replication and leads to cell death in primary cells.
Host gene expression profiling
To further elucidate the cellular mechanisms in relation to P 4 -treated cells infected with HIV-1 or co-infected with HSV-2, mRNA gene expression profiling of major chemokines, cytokines and apoptosis-specific biological markers were analyzed.
Figure 5
Progesterone effects on antiviral efficacy. (A) HIV-1-infected cells were cultured with and without P 4 for 21 days. Similarly, another P 4 -treated HIV-infected cells are cultured in the presence of HIV-1 replication inhibitor AZT. In both, HIV titer was measured at day zero to day 21 (5 intervals) using PerkinElmer Quantitative Enzyme Immuno p24 Assay. At each time point, three replicates were measured and means were plotted in the bar graph. P 4 -treated cells had significant (P < 0.01) higher viral load compared with P 4 -untreated cells. AZT inhibits HIV replication in the absence of P 4 but significantly ( *** P < 0.001) increased virus titer as observed in P 4 -treated cells. (B) Similar experimental conditions of (A) were repeated for HSV/HIV co-infections. For inhibition studies in addition to AZT, valacyclovir (to inhibit HSV-2) was used. Similar trend was observed. P 4 -treated cells had significantly ( *** P < 0.001) higher viral load compared with no P 4 cells. AZT and valacyclovir inhibit HIV/HSV-2 replication in no P 4 , but significantly ( *** P < 0.001) increased virus titer observed in P 4 -treated cells.
A total of 84 genes encoding inflammatory cytokines/receptors, chemokines/receptors and others involved in inflammation were analyzed using the Human Inflammatory Cytokines and Receptors PCR Array. Cells were either P 4 treated or untreated and infected with HIV-1 or HSV-2/HIV-1 for 7 days. The total nucleic acid was extracted, normalized and analyzed. Data were pooled from each experimental group (uninfected, NH-HIV-1, P 4 -HIV-1, NH-HIV-1/HSV-2 and P 4 -HIV-1/HSV-2) and analyzed with Web-based RT 2 profiler PCR array data, version 3.5. Gene expression was evaluated on the basis of 2-fold upregulation or downregulation compared with uninfected controls. Based on earlier observations, P 4 -treated cells infected with HIV-1 and HSV-2 could modulate certain genes in support of pathogenesis. Hence, our analysis was focused on host gene expression profile for P 4 -treated cells with HIV-1 or HSV-2 co-infections. Our results indicate that relatively few genes (CCL15, CCL19, CCR6, IL36A and IFNA2) were differentially expressed with HIV infection (NH-HIV or without P 4 treatment). Interestingly, when the expression profile was compared with P 4 -treated HIV-1-infected cells, several inflammatory genes were 2-to 15-fold upregulated (P < 0.05) (Fig. 7A) . Notably, chemokines CCL11, CCL13 and CCL23 and the receptors CCL13, CCR3, CCR6, CX3CR1 and XCR1 were 2-to 6-fold upregulated (P < 0.05) compared with HIV-1-infected cells without P 4 treatment or uninfected P 4 -treated controls. The cytokines IL36B and receptor IFNA2 were also 6-to 12-fold upregulated for HIV-1-infected P 4 -treated cells. In co-infection studies, chemokine and cytokine levels in HIV-1-infected and P 4 -treated cells were upregulated 2-410 higher than only HIV-1 infection (Fig. 7B) . Notably, several-fold increase of CCL4, CXCL9, CCR5 and CXCR1 expression was observed. The cytokines IL22, IL10RA, IL13, IL13RA1, IL5RA and IL9 were 15-to 166-fold upregulated.
To identify host factors specifically involved in cell death due to infection, similar to the inflammatory response PCR array, an apoptosis PCR array of 84 genes was analyzed. For analysis, data were pooled from each experimental group (uninfected, NH-HIV-1, NH-HSV, NH-HIV-1/HSV-2, P 4 -control, P 4 -HIV-1 and P 4 -HIV-1/HSV-2). To elucidate the expression of apoptotic genes in cells co-infected with HSV-2/HIV-1, differential gene expression was analyzed and compared with the expression profile of P 4 -treated cells. Although most of the genes were not differentially expressed in cells infected with HIV-1 or HSV-2 alone, downregulation of anti-apoptotic factor BCL2L10 was consistently observed (>2 fold) with P 4 -treated cells for both viruses (Fig. 8) . In addition, TNFRSB10B was downregulated (>2 fold) for HSV-2-infected cells with P 4 treatment. In cells co-infected with HIV-1 and HSV-2, few other genes were upregulated, and genes BCL2L10 and TNFRSB10B were downregulated (>2 fold) for HSV-2/HIV-1-infected cells with P 4 . The downregulation of Bcl-2 was further Figure 6 HIV-1 replication kinetics in primary PBMC cells either untreated (NH) or treated with progesterone (P 4 ). (A) HIV-1 p24 levels are significantly higher (P < 0.05) for P 4 -treated donors (2,3) compared with NH. For donor 1, there was no significant differences in HIV-1 p24 levels between NH and P 4 treatment. (B) Measure of HIV-1 p24 levels in HSV-2/HIV-1 co-infected donors had significantly low (P < 0.01) p24 levels in P 4 -treated cells compared with NH. Error bars represent the standard errors of the means, and samples that are significant (*) and very significant (**) as determined by unpaired t-test. Genes were evaluated on the basis of the criteria of at least a 2-fold upregulation or downregulation compared with uninfected control. Error bars represent the standard errors of the means, and statistical significance of P < 0.05 was determined by ANOVA. confirmed with qPCR and at the protein level by Western blot analysis.
P 4 regulation of Bcl-2 mRNA and protein levels
To confirm the PCR array data of Bcl-2 down-regulation by P 4 , we performed qPCR for Bcl-2 mRNA expression in P 4 -treated cells infected with HIV-1 or co-infected with HSV-2. At 7 d.p.i, RNA was extracted and quantified by GAPDH normalization. Different patterns of host gene expression were observed (Fig. 9A) . In cells not treated with P 4 , consistent increase of Bcl-2 was observed for HIV-1-or HSV-2-infected cells. Cells treated with P 4 had significant (P < 0.05) down-regulation of Bcl-2 (P 4 uninfected, infected with HIV or HSV-2 and HSV-2/HIV-1). These observations were further confirmed at the protein level using immunoblotting, which showed that P 4 -treated uninfected cells and infected with HSV-2/HIV-1 had lower expression of Bcl-2 than P 4 -untreated cells (Fig. 9B) , and densitometry was performed on bands using ImageJ software (Fig. 9C ). Cells treated with P 4 and infected with HIV-1 or HSV-2 show Bcl-2 expression due to the fact virus-host interaction this phenomenon diminishes at later infection time point. In addition, caspase 3 protein expression was evaluated to confirm extensive cell death of co-infected cells. As expected, increased caspase-3 protein expression (Fig. 9B) was noted with co-infected cells treated with P 4 or untreated.
Increased association of P 4 with PRE region of Bcl-2 promoter
This is the first study to show that P 4 treatment augments HIV-1 replication, which increases several folds in the presence of HSV-2 co-infection by the downregulation of the Bcl-2 molecule. We wanted to explore the mechanism of Bcl-2 down-regulation by P 4 treatment. Previously, it was reported that PRE is present in the Bcl-2 promoter thereby modulating Bcl-2 gene expression in P 4 -treated cells. To test whether co-infection in the presence of P 4 increases the association of transcription factors with PRE, nuclear proteins were extracted from cells cultured with or without P 4 and infected with HIV-1, HSV-2 or co-infected for 4 h and analyzed. The Bcl-2 promoter region of P 4 response element (PRE) was identified through the Web portal Transcription Element Search Site (TESS, 2011) . PCR was performed to amplify the 242 bp fragment of the Bcl-2 promoter containing the PRE and confirming the presence of the sequence within the amplified product. The biotinylated PRE probes were designed for binding in electrophoretic mobility shift assay (EMSA). Extracted nuclear proteins from P 4 -untreated (uninfected and infected with HIV-1, HSV-2 or co-infected) or P 4 -treated (P 4 uninfected and infected with P 4 -HIV-1, P 4 -HSV-2 or P 4 -co-infected) cells of different experimental conditions (lanes 1-8) were incubated with biotinylated PRE probe or mutant probe (1a-8a) of transcription factor-binding region for determining PRE association. The PRE probe and mutant probe were loaded as pairs for each experimental condition, in which lanes 1-4 represent no P 4 treatment and lanes 5-8 indicate treatment with P 4 . It was inferred from Fig. 10 that DNA-protein complex was formed when the biotin labeled probe was incubated with nuclear extract (4-8). In lane 9, incubation with excess of cold unlabeled probe (100-fold) decreased labeled probe binding, demonstrating specificity. In addition, mutant labeled probe (lanes 1a-8a) increased binding of other nuclear proteins. These data indicate that nuclear factors induced by P 4 bind to Bcl-2 promoter specifically.
Discussion
The use of progestin (P 4 analog) as contraceptive pills for HIV-1-positive women has been extensively debated recently with regard to its ability to increase HIV-1 risk or not (Colvin & Harrison 2015 , Morrison et al. 2015 , Ralph et al. 2015 . Some studies indicate no link between contraceptive use and risk of HIV-1 (Heffron et al. 2013 , whereas others reported significant risk with contraceptive use (Heffron et al. 2012 , Haddad et al. 2014 . Recently, by examining individual participant data instead of an aggregate of different studies, an increase in risk was found to be associated with the use of P 4 -containing contraceptives (Morrison et al. 2015) . Considering the immediate need in the prevention of HIV-1 in women, we investigated the basic mechanism of P 4 effects on HIV-1 pathogenesis and with co-infection of HSV-2. First, we investigated the cell type that could infect HIV-1 and HSV-2. Previously, it was shown that CEMss cell line is capable of infection by these two viruses (Legoff et al. 2007) . We tested the infectivity of these two viruses at the indicated (5 ng/mL of HIV-1 p24 or 1 p.f.u. HSV-2) concentrations, which were normalized for optimal infectivity after multiple experiments. Infectivity was determined by rise in titer from time zero. To evaluate the effects of steroid hormones on replication of HIV-1 and HSV-2, we tested testosterone and estradiol along with P 4 . The measurable HIV-1 p24 levels at 7 d.p.i in both untreated and hormone-treated cultures indicate no inhibition of hormones for HIV-1 replication. In co-infected cultures, we quantified both viruses simultaneously using an in-house multiplex quantitative TaqMan assay. An increase in virus titer was observed for both viruses from time zero and could be quantitated. In addition, HIV-1 viral load levels for cultures with and without hormone treatment showed a similar trend compared with p24 quantification (Fig. 1A  and B) . Although our present work focuses on P 4 , E 2 and testosterone hormones significantly increase HIV-1 viral load. Interestingly, E 2 or E 2 /P 4 mix increase HSV-2 viral load but not P 4 or testosterone, which may require further functional studies to validate HSV-2 replication kinetics in the presence of hormones.
Previously, several studies had indicated that P 4 or its synthetic form increased HIV-1 susceptibility or risk of infection (Asin et al. 2008 , Ramjee & Wand 2012 , Ferreira et al. 2014 ) in a macaque model using subcutaneous implants of P 4 which increased vaginal SIV transmission several fold (Marx et al. 1996) . Similar to these earlier studies, we also observed that treatment with steroid hormones increased HIV-1 viral load levels in culture supernatants. Several studies have shown that HSV-2 infection increases HIV-1 acquisition (Schacker et al. 1998 , Freeman et al. 2006 and pathogenesis (Sartori et al. 2011 , Rollenhagen et al. 2014 . Hence, HSV-2-infected individuals are at high risk for HIV-1 co-infection and that HSV-2 incidence among HIV-1 sero-discordant couples increases the risk of HIV-1 transmission (Muiru et al. 2013) . To verify this observation made at the population level, using an in vitro cell culture system, we tested several combinations of hormone and virus treatment to determine their effect on HIV-1 viral load. In cells co-infected with HSV-2 and or vice versa, we observed significant differences in viral load between the different combinations of hormone treatment ( Fig. 2A, B, C and D) except cells treated with E 2 (Fig. 2C) , P 4 and testosterone (Fig. 2B) . It is interesting to note that P 4 supports HIV-1 replication in cells treated with P 4 only ( Fig. 2A) or mixed with E 2 /P 4 ( Fig. 2A, C and D) . Conversely, E 2 supports HSV-2 replication in cells treated with E 2 only or mixed with E 2 /P 4 (Fig. 2B) . Although sex hormones support HIV-1 or HSV-2 replication, significant cell death was noted in co-infected cultures at 14 d.p.i of P 4 -treated cells. We ruled out hormone toxicity by cell viability analysis from multiple experiments with and without P 4 treatment and co-infection with HIV-1 or HSV-2. Up to day 9, >85% cells were viable (Figs 3  and 4) . Thus, in early part of HIV-1 infection (up to day 9), P 4 did not decrease the cell viability but augments HIV-1 replication. However, significant loss of cells was noted with co-infected cultures treated with P 4 . When we compared cell viability with p24 levels of co-infected cells, lower p24 levels were noted with P 4 and E 2 /P 4 treatment at 14 d.p.i. (Fig. 3) , which may be due to the decrease in cell numbers as the infection progresses.
Previous studies had reported that the use of P 4 -onlybased contraception may be associated with a small risk of HIV-1 infection for patients on antiviral therapy. Even though recent reports indicate that the contraceptive DMPA increases risk of HIV-1, there is no link between HSV-2 shedding, antiviral therapy and contraceptive use (McClelland et al. 2002 , Morrison et al. 2007 . In this study, we investigated the effect of ARVs in P 4 -treated cells. In cell cultures, it was observed that p24 levels decreased with AZT (inhibitor of HIV-1) or valacyclovir (inhibitor of HSV-2) treatment. However, in P 4 -treated cells, a significant increase in HIV-1 p24 levels were noted (Fig. 5) for HIV-1 or HIV-1/HSV-2 co-infections, which is in agreement with earlier observations that hormonal contraceptive users had lower viral load reduction than non-contraceptive users (Johnson et al. 2011) .
To further confirm the effects of P 4 on HIV-1, we obtained PBMCs from three blood donors, treated them with P 4 and infected them with HIV-1 alone or co-infected with HSV-2. We found that there were significantly higher p24 levels when the cells were exposed to P 4 (Fig. 6A) . Similarly, when PBMCs are co-infected with HSV-2 and exposed to P 4 , significant cell death and lower p24 levels were observed (Fig. 6B ). This observation with primary cells confirms our earlier finding with CEMss cell line (Fig. 3) . It should also be noted that these findings are not consistent for all donors suggesting that there may be donor-to-donor variations.
The P 4 -exposed cells infected with HIV-1 or co-infected with HSV-2 upregulate certain inflammatory cytokines and chemokines. Notably, upregulation of CCL23 was observed with HIV-1/P 4 -treated cells, which have not been shown previously in the context of HIV-1 infection. Upregulation of other pro-inflammatory cytokines, such as XCR1 supports HIV-1 replication (Vasilescu et al. 2007) , and IL-36β is indicative of the activation of the MAPK and NF-κB pathway (Tripodi et al. 2012) . These results suggest that P 4 induces pro-inflammatory responses for HIV-1 infection (Fig. 7A) . When cells are co-infected with HSV-2, specific chemokines such as CCL4 and CXCL9 were upregulated (Fig. 7B) . Our observations support the previous studies in that CXCL9 upregulation was observed in HSV-2 infection (Huang et al. 2012 , Rollenhagen et al. 2014 ) and activation of HIV-1 in target cells. In addition, elevation of IL22 and IL5 are indicative of active replication of HIV-1 or HSV-2, which was reported previously. These results suggest that P 4 plays an important role in cellular immunity to infection.
We focused our attention on the extensive cell death in P 4 -treated and co-infected cultures. We used the apoptosis array to identify biomolecules involved in cell death. We observed Bcl-2 down-regulation by P 4 , which may lead to active replication of HIV-1 or HSV-2 in co-infected cells with subsequent cell death (Fig. 8) . Several other studies have reported that Bcl-2 down-regulation by HIV-1 leads to oxidative stressmediated apoptosis and subsequent depletion of CD4T cells (Strack et al. 1996 , Cummins & Badley 2010 . In addition, previously it was reported that downregulation of Bcl-2 by HSV-2 leads to low productive infection and apoptosis (Sciortino et al. 2006) . In this study, we also observed similar effects of lower viral loads and extensive cell death with co-infections. The down-regulation of Bcl-2 by P 4 and co-infection was subsequently confirmed by qPCR and Western blot ( Fig. 9A and B) . To further support our observation that P 4 treatment leads to cell death, we noted increased caspase-3 expression in co-infected cells, which was reported previously for both HIV-1 and HSV-2 (Cicala et al. 1999 , Jones et al. 2003 .
The data presented here clearly show that P 4 supports the replication of two synergistic viruses. Previously, it was shown that Bcl-2 may have a PRE in its promoter sequence (Viegas et al. 2004 , Yin et al. 2007 ). We show PRE-like sequence in Bcl-2 promoter region of P 4 -treated cells (Fig. 10) . This observation supports the notion that P 4 has a role in transcriptional regulation of Bcl-2. In HIV-1/ HSV-2 co-infected cells, the combined effects of viral and P 4 may be one of the mechanisms that may augment viral
